AbbVie Raises 2026 Earnings Guidance, Boosting Stock
AbbVie (ABBV) shares rose approximately 2% in premarket trading after the company raised its full-year earnings guidance. The increase was driven by strong performance from newer immunology drugs Skyrizi and Rinvoq, which offset declining sales of its former top-selling drug, Humira.
Tickers: $ABBV
Topics: drug sales earnings outlook pharmaceuticals stock performance